Dial-in number to the teleconference and a conference ID will be received by registering on the link below:

https://conference.financialhearings.com/teleconference/?id=5003819

The presentation will also be webcast and can be accessed from the following web address:

https://ir.financialhearings.com/devyser-diagnostics-q3-report-2023

Speakers: CEO Fredrik Alpsten and CFO Sabina Berlin

The information was submitted for publication, through the agency of the contact persons below, on October 30, 2023, at 08:00 CET.

For more information, please contact:

Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46706 67 3106

Sabina Berlin, CFO
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519502

About Devyser

Devyser develops, manufactures, and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of many genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time, and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of Devyser's business model, which is a prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden. The company has eight in-house sales offices in Europe and the US, and a CLIA certified laboratory in Atlanta, Georgia. In August 2022, Devyser's quality management system was certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB. 

For more information, visit www.devyser.com.